Respira Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Respira Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05567367
- Locations
- 🇦🇺
Nucleus Network, Burnet Institute, Prahran, Victoria, Australia
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
Phase 2
Completed
- Conditions
- Pulmonary Arterial Hypertension
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Respira Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05343637
- Locations
- 🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇦🇺Royal Hobart Hospital, Hobart, Tasmania, Australia
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
Phase 2
Active, not recruiting
- Conditions
- Pulmonary Arterial Hypertension
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Respira Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04266197
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath